A state-of-the art HIV pill containing Dolutegravir‚ already widely used in rich countries‚ is set to become more quickly available at an affordable price in SA‚ thanks to an agreement announced by UNAIDS in New York on Thursday night.
The deal guarantees a maximum price of $75 per person per year for three-in-one pills containing Dolutegravir‚ Tenofovir and Lamivudine‚ made by pharmaceutical companies Mylan and Aurobindo under licence from Viiv Healthcare.
The development is important because it increases competition for SA’s next AIDS drug tender and is expected to help push down the cost of HIV treatment. It is also good news for patients‚ as recent research has shown Dolutegravir is more effective and better tolerated than antiretrovirals such as Efavirenz and Nevirapine.
Read more on Business Day
HIV drug to be more affordable
A state-of-the art HIV pill containing Dolutegravir‚ already widely used in rich countries‚ is set to become more quickly available at an affordable price in SA‚ thanks to an agreement announced by UNAIDS in New York on Thursday night.
The deal guarantees a maximum price of $75 per person per year for three-in-one pills containing Dolutegravir‚ Tenofovir and Lamivudine‚ made by pharmaceutical companies Mylan and Aurobindo under licence from Viiv Healthcare.
The development is important because it increases competition for SA’s next AIDS drug tender and is expected to help push down the cost of HIV treatment. It is also good news for patients‚ as recent research has shown Dolutegravir is more effective and better tolerated than antiretrovirals such as Efavirenz and Nevirapine.
Read more on Business Day
Would you like to comment on this article?
Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Trending
Latest Videos